Geneva, June 16 -- International Clinical Trials Registry received information related to the study (NCT07003022) titled 'Phase ? Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC' on June 2.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Fudan University
Condition:
Colo-rectal Cancer
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
Intervention:
Drug: cadonilimab combined with an anti-angiogenic agent, which is selected by the investigator from bevacizumab, regorafenib, or fruquintinib.
Recruitment Status: ...